Abstract:Metabotropic glutamate receptor 7 (mGlu7) is the most highly conserved and abundantly expressed mGlu receptor in the human brain. The presynaptic localization of mGlu7, coupled with its low affinity for its endogenous agonist, glutamate, are features that contribute to the receptor's role in modulating neuronal excitation and inhibition patterns, including long-term potentiation, in various brain regions. These characteristics suggest that mGlu7 modulation may serve as a novel therapeutic strategy in disorders of cognitive dysfunction, including neurodevelopmental disorders that cause impairments in learning, memory, and attention. Primary mutations in the GRM7 gene have recently been identified as novel causes of neurodevelopmental disorders, and these patients exhibit profound intellectual and cognitive disability. Pharmacological tools, such as agonists, antagonists, and allosteric modulators, have been the mainstay for targeting mGlu7 in its endogenous homodimeric form to probe effects of its function and modulation in disease models. However, recent research has identified diversity in dimerization, as well as trans-synaptic interacting proteins, that also play a role in mGlu7 signaling and pharmacological properties. These novel findings represent exciting opportunities in the field of mGlu receptor drug discovery and highlight the importance of further understanding the functions of mGlu7 in complex neurologic conditions at both the molecular and physiologic levels. SIGNIFICANCE STATEMENT: Proper expression and function of mGlu7 is essential for learning, attention, and memory formation at the molecular level within neural circuits. The pharmacological targeting of mGlu7 is undergoing a paradigm shift by incorporating an understanding of receptor interaction with other cis- and trans- acting synaptic proteins, as well as various intracellular signaling pathways. Based upon these new findings, mGlu7's potential as a drug target in the treatment of cognitive disorders and learning impairments is primed for exploration.

Mglur7: the New Player Protecting the Central Nervous System

Therapeutic Potential for Metabotropic Glutamate Receptor 7 (mGlu 7 ) Modulators in Cognitive Disorders

mGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders

Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective

Molecular Recognition of Metabotropic Glutamate Receptor Type 1 (mglur1): Synergistic Understanding with Free Energy Perturbation and Linear Response Modeling

Group III metabotropic glutamate receptors: guardians against excitotoxicity in ischemic brain injury, with implications for neonatal contexts

AMN082 Promotes the Proliferation and Differentiation of Neural Progenitor Cells with Influence on Phosphorylation of MAPK Signaling Pathways

Dynamics and Modulation of Metabotropic Glutamate Receptors.

Glutamate-regulated Behavior, Transmitter Release, Gene Expression and Addictive Plasticity in the Striatum: Roles of Metabotropic Glutamate Receptors

Activation of mGluR5 Attenuates NMDA-Induced Neurotoxicity through Disruption of the NMDAR-PSD-95 Complex and Preservation of Mitochondrial Function in Differentiated PC12 Cells

Metabotropic glutamate receptors (mGluRs) in epileptogenesis: an update on abnormal mGluRs signaling and its therapeutic implications

Metabotropic glutamate receptors and related nervous diseases

Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders

Mglur7 Undergoes Rapid Internalization in Response to Activation by the Allosteric Agonist AMN082

Targeting Metabotropic Glutamate Receptor 7 Promotes Neurogenesis

Genomic Structure of Metabotropic Glutamate Receptor 7 and Comparison of Genomic Structures of Extracellular Domains of Mglur Family

Protective Effects of Mglur5 Positive Modulators Against Traumatic Neuronal Injury Through PKC-Dependent Activation of MEK/ERK Pathway

Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes.

Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases

Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders

Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo.